ClinicalTrials.gg
RecruitingNCT06456593ENHANCE-CDUpdated Apr 27, 2026

Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

A Phase 2 interventional study of Obefazimod and Placebo in Moderately to Severely Active Crohn Disease, sponsored by Abivax S.A.. Recruiting at 149 sites in 12 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-27.

Sponsored by Abivax S.A. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
212
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 660 studies in Crohn Disease with a site in United States — 122 open to participants now, 163 under way, 35 of them phase 3. Crohn Disease · United States.

Planned enrollment
124th of 528
212 · median 60
Started
2024
with 37 others
Phase 2
141 of 660
23 open now
Primary completion
2026-12
later than 30 of 162 live
Registered
580th of 660
by date

Among the 660 studies in Crohn Disease with a site in United States, this one is the 124th largest by planned enrollment of the 528 interventional ones that give a count, is one of 38 that started in 2024, is one of 141 in phase 2, reaches primary completion later than 30 of the 162 other live ones, and was the 580th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

122 of the 660 studies in Crohn Disease with a site in United States are open now. Recruiting first, the newest first:

117 more — sign in →

All 122 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 660 studies in Crohn Disease with a site in United States, or all of them as a file.
02

Study summary

This study has 3 treatment phases, a 12-Week Induction Phase, a 40-Week Maintenance Phase, and a 48-Week Extension Phase.

The objective is to evaluate the efficacy and safety of obefazimod compared to placebo as induction and maintenance therapy in subjects with moderately to severely active CD after inadequate response (no response, loss of response, or intolerance) to conventional therapies and/or advanced therapies.

The primary objective for the 48-Week Extension Phase is to evaluate the safety and tolerability of obefazimod compared with placebo in subjects who are enrolled in the Extension Phase.

03

Conditions studied

  • Moderately to Severely Active Crohn Disease

Browse trials for

Keywords

  • Crohn Disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female (at birth) 18 to 75 years old and able to understand, sign, and date the written voluntary at the visit prior to any protocol-specified procedures
  2. Able and willing to comply with study visits and procedures as per protocol.
  3. Confirmed and documented diagnosis of CD based on endoscopy and histology reports.
  4. Moderately to severely active CD as defined by 220 ≤ CDAI ≤ 450 and SES-CD ≥ 6 for ileo-colonic or colonic disease or SES-CD ≥ 4 for isolated ileal disease (per central reading).
  5. Documented inadequate response (defined as lack of response or loss of response or intolerance) to at least one of the following treatments: (CS), (IS), biologic or biosimilar therapies, or janus kinase (JAK) (note: failure to only 5-aminosalicylic acid [5-ASA] is not accepted)
  6. Women of (WOCBP) and male subjects with WOCBP partner must agree to comply with requirements as stated in section 4.5 (contraception) of this protocol.
  7. Subject should be affiliated to a health insurance policy whenever required by a participating country or state.
  8. Subject is able and willing to comply with usual public recommendations for sun protection.

Exclusion criteria

Exclusion Criteria:

Subjects who meet any of the following exclusion criteria will be excluded from the study:

  1. subject who is pregnant or breast-feeding at screening, or intends to become pregnant during the study; or male subject with WOCBP partner who intends to be pregnant during the study.
  2. Current diagnosis of ulcerative colitis (UC) or indeterminate colitis
  3. CD without ileal and/or colonic involvement
  4. Untreated active external or perianal fistula or abscess. Stable fistula without abscess and with minimal or low drainage may be enrolled. Recent cutaneous and perianal abscesses are not exclusionary if drained and adequately treated at least 3 weeks before screening colonoscopy or 8 weeks before screening colonoscopy for intra-abdominal abscesses, if no additional surgery is anticipated.
  5. Symptomatic bowel stricture and/or stenosis not passable in endoscopy
  6. Related to CD surgery:

    1. Current stoma or ileoanal pouch
    2. More than 2 missing complete segments of the following 5 segments: terminal ileum, right colon, transverse colon, left colon, and sigmoid and rectum
    3. Combined previous small bowel resections > 100 cm
    4. Surgical bowel resection within the past 3 months prior to baseline
    5. Any other manifestation that might require surgery while enrolled in the study
  7. Related to CD treatments:

    1. Subject who is currently treated with prohibited concomitant therapies for CD as described in the study protocol
    2. Subject who has previously received natalizumab (or any other α4β1 integrin agonist)
    3. Subject who has failed more than three advanced therapies for the treatment of CD, or two different mechanisms of action for advanced therapies of CD
  8. History of, or active, including nonmelanoma skin cancer (subjects with a 5-year disease-free survival are eligible)
  9. History of colonic cancer or colonic low grade or high grade dysplasia adenomatous polyps, and/or at the screening endoscopy, evidence of low grade or high grade dysplasia adenomatous polyps (fully removed or not)
  10. Subject with history of, or diagnosed with, the following during screening: primary sclerosing cholangitis, hepatitis, or primary biliary cirrhosis
  11. Serious illness requiring hospitalization (not related to CD) within 4 weeks prior to screening
  12. Subject with the following infectious conditions:

    1. Chronic or recurrent Grade 3 or Grade 4 infection within the last 2 months prior to screening or history of opportunistic infection while not on therapy
    2. Herpes zoster reactivation within the last 2 months prior to screening
    3. Active infection at screening or any major episode of infection that required hospitalization or treatment with IV antibiotics within 1 month of screening or during screening (fungal infection of nail beds is allowed)
    4. Positive assay or stool culture for pathogens (ova and parasite examination, bacteria) that required treatment per local medical practice or positive test for Clostridioides difficile (C. difficile) toxin at screening.
    5. Subject with (HIV) infection
    6. Acute or chronic infection at screening (positive for hepatitis B surface antigen [HbsAg] or negative for HbsAg and positive for anti-hepatitis B core antibody in conjunction with detectable hepatitis B virus [HBV] deoxyribonucleic acid [DNA], or detectable HBV DNA).
    7. Acute or chronic virus (HCV) infection as defined by positive for hepatitis C antibody (subjects successfully treated and without recurrence ≥ 1 year with no detectable HCV RNA [assessed centrally] are eligible)
    8. Active tuberculosis (TB) or untreated latent TB (For subjects with positive or intermediate QuantiFERON test)
  13. Subject with uncontrolled ischemic heart disease and/or a history of congestive heart failure
  14. Subject with a known family or personal history of congenital or acquired long syndrome, or subjects with a marked baseline prolongation of QT/ heart rate-corrected QT (QTc) interval
  15. Subject with a history of torsade de pointe (TdP)
  16. Acute or chronic pulmonary, hepatic, or renal functional abnormality, encephalopathy, neuropathy or unstable central nervous system pathology such as seizure disorder, or any other clinically significant medical problems.
  17. Subjects who received within 3 months prior to screening and/or subject who is planning to receive such a vaccine during the study duration
  18. Acute or chronic pancreatitis
  19. Subject with the following hematological and biochemical laboratory parameters obtained during the screening period:

    1. ≤ 8.0 g/dL1
    2. \< 750/mm3
    3. \< 100,000 /mm3
    4. \< 60 mL/min/1.73 m2
    5. Total serum > 1.5 x (except if related to pre-existing and documented Gilbert syndrome)
    6. (AST) and/or alanine aminotransferase (ALT) > 2 x ULN
  20. Subject who does not meet the requirements prior to the screening endoscopy as described in the prohibited medication section of the study protocol
  21. Use of any or nonregistered product within 3 months or within 5 halflives preceding baseline, whichever is longer, and during the study.
  22. Subjects previously treated with obefazimod or with a known to the active substance or to any of the
  23. Illicit drug or alcohol abuse or dependence
  24. Subject who is committed to an institution by virtue of an order issued either by the judicial or the administrative authorities
  25. Any condition, which in the opinion of the investigator, could compromise the subject's safety or adherence to the study protocol
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
212 participants (estimated)

Study arms

  • Experimental
    Obefazimod 50mg

    Obefazimod 50mg given once-daily (QD) in subjects with moderately to severely active Crohn's disease (CD)

    Drug: Obefazimod

  • Experimental
    Obefazimod 25mg

    Obefazimod 25mg given once-daily (QD) in subjects with moderately to severely active Crohn's disease (CD)

    Drug: Obefazimod

  • Experimental
    Obefazimod 12.5mg

    Obefazimod 12.5mg given once-daily (QD) in subjects with moderately to severely active Crohn's disease (CD)

    Drug: Obefazimod

  • Placebo comparator
    Placebo

    Placebo given once-daily (QD) in subjects with moderately to severely active Crohn's disease (CD)

    Other: Placebo

Interventions

  • Obefazimod is administered once-daily in fed condition (ideally at the same time in the morning).

  • OtherPlacebo

    Matching placebo will be administered QD in fed condition (ideally at the same time in the morning).

06

What researchers measure

Primary outcomes

  1. Induction and maintenance Phase Efficacy- Crohn's Disease Activity Index (CDAI)

    Change from baseline in Crohn's Disease Activity Index (CDAI) score at Week 12 and Week 52 The CDAI total score ranges from 0 to over 600. Higher scores mean a worse outcome.

    Time frame: Week 12 and week 52

  2. Maintenance Phase Efficacy - Simple Endoscopic Score for Crohn's disease (SES-CD)

    Change from baseline in Simple Endoscopic Score for Crohn's disease (SES-CD) at Week 52 The SES-CD is an endoscopic grading system that consists of a composite score based on 4 components: the size of mucosal ulcers, the extent of the ulcerated surface, the endoscopic extension, and the presence of stenosis (26). Each of the 4 SES-CD components are assessed in the 5 segments of the ileum and colon: ileum, right, transverse, left, and rectum. The SES-CD is the sum of the individual scores of each of the components across the 5 segments. The total score ranges from 0 to 60. Higher scores mean a worse outcome

    Time frame: Week 52

  3. Maintenance Phase Efficacy - Endoscopic response

    Proportion of subjects with endoscopic response at Week 52

    Time frame: Week 52

  4. Maintenance Phase Efficacy - SES-CD ulcer subscore > 1

    Proportion of subjects with no SES-CD ulcer subscore \> 1 in at least one segment at Week 52

    Time frame: Week 52

  5. Maintenance Phase Efficacy - CDAI clinical remission

    Proportion of subjects with CDAI clinical remission at Week 52 Proportion of subjects with sustained CDAI clinical remission at Week 52

    Time frame: Week 52

  6. Maintenance Phase Efficacy - PRO-2 clinical remission

    Proportion of subjects with patient reported outcome (PRO)-2 clinical remission at Week 52

    Time frame: Week 52

  7. Maintenance Phase Efficacy - CDAI clinical response

    Proportion of subjects with CDAI clinical response (CDAI decrease from baseline ≥ 100 points) at Week 52

    Time frame: Week 52

  8. Maintenance Phase Efficacy - PRO-2 clinical response

    Proportion of subjects with PRO-2 clinical response (≥ 30% decrease in average daily PRO-2 score (AP + SF) and both no higher than baseline) at Week 52

    Time frame: Week 52

  9. Maintenance Phase Efficacy - CDAI clinical response and endoscopic response

    Proportion of subjects with CDAI clinical response and endoscopic response at Week 52

    Time frame: Week 52

  10. Maintenance Phase Efficacy - endoscopic remission

    Proportion of subjects with endoscopic remission at Week 52

    Time frame: Week 52

  11. Extension Phase Safety- Adverse events

    Incidence of all treatment-emergent adverse events (TEAEs), serious adverse events (SAEs) and causally related TEAEs/SAEs Incidence of adverse events (AEs) leading to discontinuation

    Time frame: Weeks 64, 76, 88,100 and EOS

  12. Extension Phase Safety - Hematology and coagulation

    Number of patients with clinically-significant abnormal laboratory parameters. Hematology: Hematocrit, hemoglobin, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, mean corpuscular volume, platelet count, red blood cells; white blood cells Coagulation: International normalized ratio, activated partial thromboplastin time, fibrinogen, prothrombin time

    Time frame: Weeks 64, 76, 88,100 and EOS

  13. Extension Phase Safety - Biochemistry

    Number of patients with clinically-significant abnormal laboratory parameters. Albumin, total protein, aspartate aminotransferase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP), total bilirubin, gamma glutamyl transferase (GGT), lactate dehydrogenase (LDH), lipase, amylase, creatinine, creatinine clearance, urea, chloride, bicarbonate, sodium, potassium, calcium, phosphate, uric acid, glucose, total cholesterol, LDL cholesterol (direct), HDL cholesterol, triglycerides, creatine phosphokinase (CPK), high sensitivity troponin I and T, N-terminal prohormone of brain natriuretic peptide (NT-proBNP)

    Time frame: Weeks 64, 76, 88,100 and EOS

Secondary outcomes

  1. Induction Phase Efficacy - SES-CD

    Change from baseline in Simple Endoscopic Score for Crohn's disease (SES-CD) at Week 12

    Time frame: Week 12

  2. Induction Phase Efficacy - Endoscopic response

    Proportion of subjects with endoscopic response at Week 12

    Time frame: Week 12

  3. Induction Phase Efficacy-SES-CD ulcer subscore > 1

    Proportion of subjects with no SES-CD ulcer subscore \> 1 in at least one segment at Week 12

    Time frame: Week 12

  4. Induction Phase Efficacy-CDAI clinical remission

    Proportion of subjects with Crohn's Disease Activity Index (CDAI) clinical remission (CDAI score \< 150) at Week 12 The total CDAI score ranges from 0 to over 600. Higher scores mean a worse outcome

    Time frame: Week 12

  5. Induction Phase Efficacy-PRO-2 clinical remission

    Proportion of subjects with patient reported outcome (PRO)-2 clinical remission (Combination of average daily abdominal pain score ≤ 1.0 plus average daily soft or liquid stool frequency ≤ 2.8 and both no higher than baseline) at Week 12

    Time frame: Week 12

  6. Induction Phase Efficacy-CDAI clinical response

    Proportion of subjects with CDAI clinical response (CDAI decrease from baseline ≥ 100 points) at Week 12 The total CDAI score ranges from 0 to over 600. Higher scores mean a worse outcome

    Time frame: Week 12

  7. Induction Phase Efficacy-PRO-2 clinical response

    Proportion of subjects with PRO-2 clinical response at Week 12

    Time frame: Week 12

  8. Induction Phase Efficacy-CDAI clinical response and endoscopic response

    Proportion of subjects with CDAI clinical response (CDAI decrease from baseline ≥ 100 points) and endoscopic response (Simple Endoscopic Score for Crohn's disease (SES-CD) decrease from baseline ≥ 50%) at Week 12 The total CDAI score ranges from 0 to over 600. Higher scores mean a worse outcome The total SES-CD score ranges from 0 to 60. Higher scores mean a worse outcome.

    Time frame: Week 12

  9. Induction Phase Efficacy - endoscopic remission

    Proportion of subjects with endoscopic remission at Week 12

    Time frame: Week 12

07

Study locations

88 of 149 sites recruiting
  • IMC Gulf Coast Gastroenterology, PC
    Fairhope, Alabama 36532, United States
    Not yet recruiting
    • Nathaniel Winstead, MD · Contact
  • Scottsdale Gastroenterology Specialists
    Scottsdale, Arizona 85260, United States
    Not yet recruiting
    • S. Jaffrey Kazi, MD · Contact
  • GI Alliance -Gurnee
    Sun City, Arizona 85351, United States
    Recruiting
    • Chirag Trivedi, MD · Contact
  • Hoag Hospital
    Irvine, California 92618, United States
    Not yet recruiting
    • Caroline Hwang, MD · Contact
  • United Medical Doctors
    Murrieta, California 92563, United States
    Recruiting
    • John Hong, MD · Contact
  • Peak Gastroenterology Associates
    Colorado Springs, Colorado 80907, United States
    Recruiting
    • Bhaktasharan Patel, MD · Contact
  • Clinical Research Of Brandon, LLC
    Brandon, Florida 33511, United States
    Recruiting
    • German Alvarez, MD · Contact
  • West Central Gastroenterology d/b/a Gastro Florida
    Clearwater, Florida 33762, United States
    Recruiting
    • Tejinder Glamour, MD · Contact
  • Auzmer Research
    Lakeland, Florida 33813, United States
    Recruiting
    • Niaz Ausaf, MD · Contact
  • Research Associates of South Florida, LLC
    Miami, Florida 33134, United States
    Recruiting
    • Alexander Veloso, MD · Contact
  • Wellness Clinical Research
    Miami Lakes, Florida 33016, United States
    Not yet recruiting
    • Lucky Flores, MD · Contact
  • Advanced Research Institute, Inc.
    New Port Richey, Florida 34653, United States
    Recruiting
    • Curtis Freedland, MD · Contact
  • Sarkis Clinical Trials - Parent
    Ocala, Florida 34474, United States
    Recruiting
    • Vishnu Reddy, MD · Contact
  • Orlando Health, Inc.
    Orlando, Florida 32806, United States
    Recruiting
    • Udayakumar Navaneethan, MD · Contact
  • GCP Clinical Research, LLC
    Tampa, Florida 33609, United States
    Recruiting
    • Alan Weintraub, MD · Contact
  • Theia Clinical Research Centers, LLC
    Temple Terrace, Florida 33617, United States
    Recruiting
    • Zubair Farooqui, MD · Contact
  • Northwestern University
    Evanston, Illinois 60208, United States
    Recruiting
    • Emanelle Bellaguarda, MD · Contact
  • University of Iowa Health Care
    Iowa City, Iowa 52242, United States
    Not yet recruiting
    • Steven Polyak, MD · Contact
  • Lucida Clinical Trials, LLC
    New Bedford, Massachusetts 02740, United States
    Recruiting
    • Jason Reich, MD · Contact
  • University of Massachusetts, Worcester
    Worcester, Massachusetts 01655, United States
    Not yet recruiting
    • Abbas Rupawala, MD · Contact
  • Henry Ford Columbus Center
    Detroit, Michigan 48202, United States
    Recruiting
    • Najwa El-Nachef, MD · Contact
  • Dartmouth-Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
    Not yet recruiting
    • Corey Siegel, MD · Contact
  • OSU Inflammatory Bowel Disease Center
    Hilliard, Ohio 43026, United States
    Not yet recruiting
    • Madalina Butnariu, MD · Contact
  • Susquehanna Research Group, LLC
    Harrisburg, Pennsylvania 17110, United States
    Not yet recruiting
    • Adnan Ahmad, MD · Contact
  • UPMC
    Pittsburgh, Pennsylvania 15213, United States
    Not yet recruiting
    • Marc Schwartz, MD · Contact
  • Frontier Clinical Research, LLC
    Uniontown, Pennsylvania 15401, United States
    Recruiting
    • Marc Happe, MD · Contact
  • Rapid City Medical Center, LLC
    Rapid City, South Dakota 57701, United States
    Recruiting
    • Blake Jones, MD · Contact
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37212, United States
    Not yet recruiting
    • Audrey Bennett, MD · Contact
  • Central Texas Clinical Research, LLC
    Austin, Texas 78705, United States
    Not yet recruiting
    • Cynthia Brinson, MD · Contact
  • Inquest Clinical Research
    Baytown, Texas 77521, United States
    Not yet recruiting
    • Haider Afzal, MD · Contact
  • Novel Research, LLC
    Bellaire, Texas 77401, United States
    Recruiting
    • Moazzam Sana, MD · Contact
  • GI Alliance
    Cedar Park, Texas 78613, United States
    Recruiting
    • Ryan Cho, MD · Contact
  • Baylor University Hospital
    Dallas, Texas 75246, United States
    Recruiting
    • Themistocles Dassopoulos, MD · Contact
  • GI Alliance - Garland
    Garland, Texas 75044, United States
    Not yet recruiting
    • Harry Sarles, MD · Contact
  • Texas Digestive Specialists
    Harlingen, Texas 78550, United States
    Recruiting
    • Nolan Perez, MD · Contact
  • Houston Methodist Hospital
    Houston, Texas 77030, United States
    Not yet recruiting
    • Bincy Abraham, MD · Contact
  • GI Alliance - Gurnee
    Mansfield, Texas 76063, United States
    Not yet recruiting
    • Moustafa Youssef, MD · Contact
  • Southern Star Research Institute, LLC
    San Antonio, Texas 78229, United States
    Not yet recruiting
    • Jeff Bullock, MD · Contact
  • Tyler Research Institute, LLC
    Tyler, Texas 75701, United States
    Recruiting
    • George Aaron DuVall, MD · Contact
  • University of Utah
    Salt Lake City, Utah 84108, United States
    Recruiting
    • John Valentine, MD · Contact
  • Richmond VA Medical Center
    Richmond, Virginia 23249, United States
    Not yet recruiting
    • William Pandak, MD · Contact
  • Gastroenterology Consultants of Southwest Virginia.
    Roanoke, Virginia 24014, United States
    Recruiting
    • Nirish Shah, MD · Contact
  • University of Washington
    Seattle, Washington 98195, United States
    Not yet recruiting
    • Scott Lee, MD · Contact
  • Hopital Universitaire de Bruxelles - Hopital Erasme
    Brussels, Belgium
    Recruiting
    • Denis Franchimont, MD · Contact
  • AZ Maria Middelares
    Ghent, Belgium
    Recruiting
    • Nele Deprez, MD · Contact
  • Universitair Ziekenhuis Gent
    Ghent, Belgium
    Not yet recruiting
    • Triana Lobaton Ortega, MD · Contact
  • UZ Leuven
    Leuven, Belgium
    Recruiting
    • Bram Verstockt, MD · Contact
  • Centre Wallonie Picarde
    Tournai, Belgium
    Not yet recruiting
    • Lena Capirchio, MD · Contact
  • CHU UCL Namur
    Yvoir, Belgium
    Recruiting
    • Jean-François Rahier, MD · Contact
  • SurGal Clinic s.r.o.
    Brno, Czechia
    Recruiting
    • Jan Ulbrych, MD · Contact
  • Vojenska nemocnice Brno
    Brno, Czechia
    Recruiting
    • David Stepek, MD · Contact
  • Hepato-Gastroenterologie HK s.r.o.
    Hradec Králové, Czechia
    Not yet recruiting
    • Miroslava Volfova, MD · Contact
  • PreventaMed s.r.o.
    Olomouc, Czechia
    Recruiting
    • Jiri Pumprla, MD · Contact
  • ISCARE a.s.
    Prague, Czechia
    Not yet recruiting
    • Milan Lukas, MD · Contact
  • Nemocnice Slany
    Slaný, Czechia
    Recruiting
    • Martin Peterka, MD · Contact
  • CHU Amiens
    Amiens, France
    Recruiting
    • Mathurin Fumery, MD · Contact
  • CHU Besançon - Hôpital Jean Minjoz
    Besançon, France
    Not yet recruiting
    • Lucine Vuitton, MD · Contact
  • CHU Clermont Ferrand - Hopital d'Estaing
    Clermont-Ferrand, France
    Recruiting
    • Anthony Buisson, MD · Contact
  • Hôpital Henri Mondor
    Créteil, France
    Recruiting
    • Mathieu Uzzan, MD · Contact
  • CHU Dijon - Hôpital Bocage Central
    Dijon, France
    Not yet recruiting
    • Maeva Charkaoui, MD · Contact
  • CHU de Grenoble - Hôpital Michallon
    Grenoble, France
    Not yet recruiting
    • Marianne Hupe, MD · Contact
  • Centre Hospitalier Départemental Vendée - Les Oudairies
    La Roche-sur-Yon, France
    Not yet recruiting
    • Morgane Amil, MD · Contact
  • Hôpital Bicêtre
    Le Kremlin-Bicêtre, France
    Not yet recruiting
    • Aurelien Amiot, MD · Contact
  • CHU Lille - Hôpital Claude Huriez
    Lille, France
    Not yet recruiting
    • Maria Nachury, MD · Contact
  • Hôpital Nord - CHU Marseille
    Marseille, France
    Not yet recruiting
    • Melanie Serrero, MD · Contact
  • Hopital Saint Eloi
    Montpellier, France
    Recruiting
    • Romain Altwegg, MD · Contact
  • CHU Nantes - Hôtel Dieu
    Nantes, France
    Not yet recruiting
    • Catherine Le Berre, MD · Contact
  • Institut des MICI
    Neuilly-sur-Seine, France
    Recruiting
    • Xavier Treton, MD · Contact
  • CHU Nice - Hôpital de l'Archet 2
    Nice, France
    Not yet recruiting
    • Adrien Nicolau, MD · Contact
  • CHU Bordeaux - Hôpital Haut-Lévêque
    Pessac, France
    Recruiting
    • David Laharie, MD · Contact
  • Centre Hospitalier Lyon Sud
    Pierre-Bénite, France
    Recruiting
    • Stephane Nancey, MD · Contact
  • CHU Saint Etienne - Hôpital Nord
    Saint-Etienne, France
    Not yet recruiting
    • Xavier Roblin, MD · Contact
  • Hopital Rangueil
    Toulouse, France
    Recruiting
    • Cyrielle Gilletta de Saint Joseph, MD · Contact
  • Hôpital de Brabois
    Vandœuvre-lès-Nancy, France
    Not yet recruiting
    • Benedicte Caron, MD · Contact
  • Charite-Campus Benjamin Franklin Medizin.Klin.I
    Berlin, Germany
    Not yet recruiting
    • Britta Siegmund, MD · Contact
  • Krankenhaus Waldfriede e. V.
    Berlin, Germany
    Recruiting
    • Carsten Buening, MD · Contact
  • Universitaetsklinikum Brandenburg an der Havel
    Brandenburg an der Havel, Germany
    Not yet recruiting
    • Stefan Lueth, MD · Contact
  • Universitaetsklinikum Erlangen
    Erlangen, Germany
    Recruiting
    • Raja Atreya, MD · Contact
  • Universitaetsklinikum Frankfurt Goethe-Universitaet
    Frankfurt am Main, Germany
    Not yet recruiting
    • Irina Blumenstein · Contact
  • Hamburgisches Forschungsinstitut fuer Chronisch Entzuendliche Darmerkrankungen
    Hamburg, Germany
    Recruiting
    • Stefanie Howaldt, MD · Contact
  • Medizinische Hochschule Hannover
    Hanover, Germany
    Recruiting
    • Ursula Seidler, MD · Contact
  • Universitaetsklinikum Heidelberg
    Heidelberg, Germany
    Not yet recruiting
    • Annika Gauss, MD · Contact
  • Universitaetsklinikum Schleswig-Holstein - Campus Kiel
    Kiel, Germany
    Recruiting
    • Stefan Schreiber, MD · Contact
  • St. Marienkrankenhaus
    Ludwigshafen, Germany
    Recruiting
    • Tanja Kuehbacher, MD · Contact
  • LMU - Campus Grosshadern
    München, Germany
    Not yet recruiting
    • Helga Toeroek, MD · Contact
  • Universitaetsklinikum Ulm
    Ulm, Germany
    Recruiting
    • Jochen Klaus, MD · Contact
  • Bekes Varmegyei Kozponti Korhaz
    Békéscsaba, Hungary
    Recruiting
    • Marta Varga, MD · Contact
  • Obudai Egeszsegugyi Centrum Kft.
    Budapest, Hungary
    Not yet recruiting
    • Robert Sike, MD · Contact
  • Pannonia Maganorvosi Centrum
    Budapest, Hungary
    Recruiting
    • Robert Schnabel, MD · Contact
  • Semmelweis Egyetem
    Budapest, Hungary
    Recruiting
    • Pal Miheller, MD · Contact
  • Semmelweis Egyetem
    Budapest, Hungary
    Not yet recruiting
    • Zsolt Tulassay, MD · Contact
  • Gyongyosi Bugat Pal Korhaz
    Gyöngyös, Hungary
    Not yet recruiting
    • Gabor Makai, MD · Contact
  • Clinfan Szolgaltato Kft.
    Szekszárd, Hungary
    Not yet recruiting
    • Agnes Salamon, MD · Contact
  • Fejer Varmegyei Szent Gyorgy Egyetemi Oktato Korhaz
    Székesfehérvár, Hungary
    Recruiting
    • Roland Fejes, MD · Contact
  • Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi IRCCS
    Bologna, Italy
    Not yet recruiting
    • Paolo Gionchetti, MD · Contact
  • Azienda Ospedaliera Universitaria Renato Dulbecco di Catanzaro
    Catanzaro, Italy
    Not yet recruiting
    • Francesco Luzza, MD · Contact
  • Ospedale San Raffaele
    Milan, Italy
    Recruiting
    • Silvio Danese, MD · Contact
  • Ospedale Sacro Cuore Don Calabria
    Negrar, Italy
    Not yet recruiting
    • Angela Variola, MD · Contact
  • Fondazione IRCCS Policlinico San Matteo
    Pavia, Italy
    Recruiting
    • Antonio Di Sabatino, MD · Contact
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS
    Roma, Italy
    Recruiting
    • Antonio Gasbarrini, MD · Contact

Showing the first 100 of 149 sites across 12 countries. Choose a country and city above to see the rest.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Dec 2026, 26 months after the start.

Of 56 industry-sponsored phase 2 interventional studies under Crohn Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's planned 26 months is below that.

Counting every sponsor, half of 83 studies reached it within 34 months; a quarter within 23 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2024
First posted
Jun 13, 2024
StartActual
Oct 30, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Apr 2028
Last update
Apr 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06456593
Lead sponsor
Abivax S.A.
Responsible party
Sponsor
First posted
Jun 13, 2024
Start date
Oct 30, 2024
Primary completion
Dec 2026 (estimated)
Completion
Apr 2028 (estimated)
Last update
Apr 27, 2026

Study contacts

Study Director
Contact
info@abivax.com
+33 (0) 1 53 83 09 63

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ABX464

Start the discussion